Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eravacycline (Primary) ; Meropenem
  • Indications Intra-abdominal infections
  • Focus Registrational; Therapeutic Use
  • Acronyms IGNITE4
  • Sponsors Tetraphase Pharmaceuticals

    • Most Recent Events

    • 14 Oct 2022 According to an Innoviva media release, XERAVA is approved by the European Commission (EC) for the treatment of complicated intra-abdominal infections in adults.
    • 15 Jan 2020 Results published in the Pharmacotherapy
    • 10 Jun 2019 According to a Tetraphase Pharmaceuticals media release, results of post-hoc analysis of two pooled phase 3 studies (IGNITE1 and IGNITE4) of XERAVA (Eravacycline) were presented at the 39th Annual Surgical Infection Society (SIS) Meeting (June 5th-8th, 2019).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top